Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05009810
Other study ID # EC2103320
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 15, 2021
Est. completion date July 31, 2022

Study information

Verified date August 2021
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate efficacy and safety of astaxanthin in 180 volunteers with refraction errors. Visual test, skin test, liver function test, renal function test, and adverse event will be evaluated before and after taking astaxanthin for 1 and 2 months.


Description:

This study will investigate efficacy and safety of astaxanthin in 180 volunteers with refraction errors. They will divided into 3 groups which are astaxanthin 4 mg group , astaxanthin 6 mg group, and placebo group. They will take the sample 1 capsule once daily for 2 months. Visual test, skin test, liver function test, renal function test, and adverse event will be evaluated before and after taking the sample for 1 and 2 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date July 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18-65 years - Refraction errors, dry eye, or blurred vision - Have a willingness to participate in the study Exclusion Criteria: - Uncontrolled disease - Have complications during the study - Have astaxanthin more than 2 weeks - Allergic to astaxanthin, seafood, or seaweed - Osteoporosis or thyroid disease - Immunodeficiency or taking immunosuppressants - Liver and kidney diseases - A person with a brain disorder, vision or hearing unusual - Pregnancy or lactation - Cannot follow the protocol - During participated in other studies

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
astaxanthin 4 mg
They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
astaxanthin 6 mg
They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
Placebo
They will take placebo 1 capsule once daily for 2 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chulalongkorn University

Outcome

Type Measure Description Time frame Safety issue
Primary Visual acuity value Measured using Snellen Chart (logarithm of the minimal angle of resolution unit) 2 months
Secondary Refractive status Measured using Auto refractometer (two digit scale) 2 months
Secondary Eye fatigue status Measured using eye fatigue questionnaire (scale 1 to 5 which are no symptom (1) to severe(5)) 2 months
Secondary Vision status Measured using Thai National Eye Institute Visual Functioning Questionnaire 25 (scale 25 to 100 which are normal (25) to worse(100)) 2 months
Secondary Skin erythema value Measured using Mexameter (skin erythema index) 2 months
Secondary Skin melanin value Measured using Mexameter (skin melanin index) 2 months
Secondary Skin humidity value Measured using Corneometer (skin humidity index) 2 months
Secondary Skin transepidermal water loss value Measured using Transepidermal water loss meter (skin transepidermal water loss index) 2 months
Secondary Aspartate transaminase value Measured aspartate transaminase value (U/L) in blood 2 months
Secondary Alanine aminotransferase value Measured alanine aminotransferase value (U/L) in blood 2 months
Secondary Alkaline phosphatase value Measured alkaline phosphatase value (U/L) in blood 2 months
Secondary Blood urea nitrogen value Measured blood urea nitrogen value (mg/dl) in blood 2 months
Secondary Creatinine value Measured creatinine value (mg/dl) in blood 2 months
Secondary Adverse events Measured using questionnaire (Yes or No) 2 months
See also
  Status Clinical Trial Phase
Completed NCT04532099 - Clinical Comparison of Two Daily Wear Frequent Replacement Silicone Hydrogel Soft Contact Lenses N/A
Completed NCT05039112 - Clinical Comparison of 2 Daily Disposable Toric Soft Contact Lenses N/A
Completed NCT03670303 - Trial of an Educational Intervention to Promote Spectacle Use Among Secondary School Children in Islamabad, Pakistan N/A
Completed NCT02255474 - Bifocal Lenses In Nearsighted Kids N/A
Not yet recruiting NCT03222661 - Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction N/A
Completed NCT04055519 - Clinical Performance Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens N/A
Recruiting NCT05049070 - Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction N/A
Completed NCT04527978 - Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1 N/A
Completed NCT01430247 - Vision Screening for the Detection of Amblyopia N/A
Recruiting NCT06077682 - Cycloplegic Refraction in Pediatric Patients With Esotropia Phase 4
Not yet recruiting NCT04077086 - Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities N/A
Completed NCT04528017 - Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 2 N/A
Withdrawn NCT04352868 - Customizing Myopia Control With Multifocal Toric Contact Lens N/A
Recruiting NCT04338880 - Academic Performance and Refractive Error
Recruiting NCT04545073 - Outcomes of a Trifocal IOL in Post-refractive Patients
Enrolling by invitation NCT05992675 - Air Optix® Night and Day® Aqua Continuous Wear
Enrolling by invitation NCT05976750 - Air Optix® Night and Day® Aqua Daily Wear
Recruiting NCT04693247 - Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction N/A
Recruiting NCT06065631 - Seeing to Learn in Sierra Leone N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A